Compare MMLP & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MMLP | ICCC |
|---|---|---|
| Founded | 2002 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 90.8M | 75.8M |
| IPO Year | 2002 | 1995 |
| Metric | MMLP | ICCC |
|---|---|---|
| Price | $2.10 | $9.77 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | ★ 46.7K | 21.8K |
| Earning Date | 04-22-2026 | 05-15-2026 |
| Dividend Yield | ★ 0.78% | N/A |
| EPS Growth | N/A | ★ 53.85 |
| EPS | N/A | ★ 0.21 |
| Revenue | ★ $1,653,009,000.00 | $26,493,169.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $46.98 |
| Revenue Growth | 0.65 | ★ 51.64 |
| 52 Week Low | $1.89 | $4.52 |
| 52 Week High | $3.54 | $10.75 |
| Indicator | MMLP | ICCC |
|---|---|---|
| Relative Strength Index (RSI) | 36.10 | 56.52 |
| Support Level | N/A | $9.29 |
| Resistance Level | $2.83 | $10.75 |
| Average True Range (ATR) | 0.23 | 0.31 |
| MACD | -0.05 | -0.06 |
| Stochastic Oscillator | 26.13 | 61.11 |
Martin Midstream Partners LP has a diverse set of operations focused on the United States Gulf Coast region. The company's business lines include terminalling, processing, storage, and packaging services for petroleum products and by-products, including the refining of naphthenic crude oil; land and marine transportation services for petroleum products and by-products, chemicals, and specialty products; sulfur and sulfur-based products processing, manufacturing, marketing, and distribution; and natural gas liquids marketing, distribution and transportation services. The company operates in four segment Terminalling and storage, Transportation, Sulfur service, and Specialty products segment. The majority of the revenue is derived from the Specialty products segment.
ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.